Nektar Therapeutics ( NKTR ) NASDAQ Global Select

Cena: 33.4 ( 36.61% )

Aktualizacja 06-25 18:10
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 137
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 99%
Ilość akcji: 190 771 000
Debiut giełdowy: 1994-05-03
WWW: https://www.nektar.com
CEO: Mr. Howard W. Robin
Adres: 455 Mission Bay Boulevard South
Siedziba: 94158 San Francisco
ISIN: US6402681083
Opis firmy:

Nektar Therapeutics, firma biofarmaceutyczna, koncentruje się na odkrywaniu i rozwijaniu leków w obszarach niezaspokojonych potrzeb medycznych w Stanach Zjednoczonych i na arenie międzynarodowej. Produkty firmy obejmują Bempegaldesleukin, agonistę szlaku interleukiny-2 (IL-2), który jest w badaniu klinicznym fazy 3 w leczeniu czerniaka przerzutowego, raka komórek nerkowych, raka pęcherzyka, raka płaskonabłonkowego komórek krwinek. Badanie kliniczne fazy 2 w leczeniu raka komórek nerkowych, niedrobnokomórkowego raka płuc i raka urotelialnego; Badanie kliniczne fazy 1/2A w leczeniu raka płaskonabłonkowego głowy i szyi; Badanie kliniczne fazy 1/2 leczenia guzów litych; oraz badanie kliniczne fazy 1B w celu leczenia Covid-19. Rozwija także NKTR-358, stymulant cytokin Treg, który jest w badaniu klinicznym fazy 2 w leczeniu rumieniowatego tocznia ogólnego i wrzodziejącego zapalenia jelita grubego, a także badanie kliniczne fazy 1B w celu leczenia atopowego zapalenia skóry i łuszczycy; NKTR-255, agonista receptora IL-15, który jest w badaniu klinicznym fazy 1/2 w leczeniu chłoniaka nieziarniczego i szpiczaka mnogiego oraz raka głowy i szyi oraz raka jelita grubego; oraz NKTR-262, agonista receptora podobnego do opłat, który jest w badaniu klinicznym fazy 1/2 w leczeniu guzów stałych, a także różnych innych kandydatów na leki. Firma ma umowy o współpracy z Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck Kgaa; i SFJ Pharmaceuticals, Inc. Nektar Therapeutics został włączony w 1990 roku i ma siedzibę w San Francisco w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 414 410 311
Aktywa: 307 966 000
Cena: 33.4
Wskaźnik Altman Z-Score: -16.4
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -3.5
Ilość akcji w obrocie: 99%
Średni wolumen: 839 801
Ilość akcji 12 406 900
Wskaźniki finansowe
Przychody TTM 93 137 000
Zobowiązania: 259 082 000
Przedział 52 tyg.: 6.45 - 37.38
Piotroski F-Score: 2
Słaby (niska jakość finansowa)
EPS: -9.4
P/E branży: 26.1
Beta: 0.61
Raport okresowy: 2025-08-06
WWW: https://www.nektar.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Mark A. Wilson Senior Vice President, Chief Legal Officer & Secretary 868 678 1972
Ms. Sandra A. Gardiner Chief Financial Officer 376 300 1966
Mr. Howard W. Robin Chief Executive Officer, President & Director 2 208 416 1953
Dr. Jonathan Zalevsky Ph.D. Chief Research & Development Officer 1 595 064 1975
Mr. Robert Bacci Senior Vice President of Human Resources & Facilities Operations 0 0
Ms. Jennifer Ruddock Chief Business Officer 0 0
Dr. Mary Tagliaferri L.Ac., M.D. Chief Medical Officer 0 1966
Vivian Wu Director of Investor Relations & Corporate Affairs 0 0
Wiadomości dla Nektar Therapeutics
Tytuł Treść Źródło Aktualizacja Link
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN FRANCISCO , Dec. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California. NKTR-255 is an investigational polymer-conjugated IL-15 agonist, that activates, proliferates and expands natural killer (NK) and CD8+ T-cells in vivo, as well as promotes the survival and expansion of memory CD8+ T cells intended to increase duration and level of response for CAR-T and cellular therapies.1,2 In this multicenter, double-blind Phase 2 study, patients were randomized to receive one of three dose regimens of NKTR-255 or placebo intravenously starting 14 days after CAR-T infusion. prnewswire.com 2024-12-07 14:00:00 Czytaj oryginał (ang.)
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO , Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR) conference, being held in Washington, D.C. from November 14-19, 2024. prnewswire.com 2024-11-18 17:30:00 Czytaj oryginał (ang.)
Multiple Catalysts Ahead For Nektar Therapeutics Nektar continues to make progress with rezpegaldesleukin, with results from the phase 2 atopic dermatitis study expected in H1'25. NKTR-255 is showing promising results in multiple oncology trials, although these are only small studies. NKTR-255 also has a potential near-term readout in the JAVELIN Bladder Medley study, although there is competition. seekingalpha.com 2024-11-14 11:11:23 Czytaj oryginał (ang.)
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year. zacks.com 2024-11-08 15:05:28 Czytaj oryginał (ang.)
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. zacks.com 2024-11-07 20:41:07 Czytaj oryginał (ang.)
Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. prnewswire.com 2024-11-07 18:15:00 Czytaj oryginał (ang.)
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting – NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 – – Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation  – SAN FRANCISCO , Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. NKTR-255 is a novel polymer-conjugated IL-15 agonist, designed to activate, proliferate and expand natural killer (NK) and CD8+ T-cells, as well as to promote the survival and expansion of memory CD8+ T cells. prnewswire.com 2024-11-07 12:15:00 Czytaj oryginał (ang.)
Nektar Therapeutics to Participate in Upcoming Investor Conferences SAN FRANCISCO , Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. prnewswire.com 2024-11-06 20:00:00 Czytaj oryginał (ang.)
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential Piper Sandler has initiated coverage on Nektar Therapeutics Inc NKTR, citing the company's lead asset rezpegaldesleukin's (REZPEG) differentiated mechanism of action. benzinga.com 2024-11-04 15:44:41 Czytaj oryginał (ang.)
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 million equity ownership in new portfolio company. prnewswire.com 2024-11-04 10:30:00 Czytaj oryginał (ang.)
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets SAN FRANCISCO , Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. prnewswire.com 2024-10-31 20:00:00 Czytaj oryginał (ang.)
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases - Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials - SAN FRANCISCO , Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO). Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that enhances the activity of regulatory T cells (Tregs) with promising dose-dependent clinical activity across multiple physician-assessed and patient-reported endpoints for AD and PsO. prnewswire.com 2024-10-29 11:00:00 Czytaj oryginał (ang.)
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia – Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved complete remission, all without detectable MRD – SAN FRANCISCO , Oct. 17, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting CD19 and CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) in Blood, the peer-reviewed medical journal of the American Society of Hematology. NKTR-255 is a novel IL-15 receptor agonist currently being studied in clinical trials in combination with cellular therapies and immune checkpoint inhibitors. prnewswire.com 2024-10-17 16:07:00 Czytaj oryginał (ang.)
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024 - New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN FRANCISCO , Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress. prnewswire.com 2024-09-25 07:30:00 Czytaj oryginał (ang.)
Nektar Management to Present at Upcoming Investor Conferences SAN FRANCISCO , Sept. 3, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: H.C. prnewswire.com 2024-09-03 13:00:00 Czytaj oryginał (ang.)
What Makes Nektar (NKTR) a New Buy Stock Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-08-13 17:00:58 Czytaj oryginał (ang.)
Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript seekingalpha.com 2024-08-10 13:04:02 Czytaj oryginał (ang.)
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading. zacks.com 2024-08-09 16:00:38 Czytaj oryginał (ang.)
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago. zacks.com 2024-08-08 22:56:07 Czytaj oryginał (ang.)
Nektar Therapeutics Reports Second Quarter 2024 Financial Results SAN FRANCISCO , Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. prnewswire.com 2024-08-08 20:15:00 Czytaj oryginał (ang.)